AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing pro

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperfo

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-allowance-of-u-s--pate

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and l

HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with

Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Out

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Ou

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers th

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and pla

U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden miss

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintain

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 develo

On August 24, 2026, the United States District Court for the Southern District of California (the &#

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and r

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-W

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises th

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises th

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Per

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperfo

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Out

ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the a

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Ou

Wall Street analysts change outlook on top names. See all rating changes, including upgrades and dow

Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises

-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s dise

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperfo

B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a B

Acadia shares rise after CHMP recommends DAYBU for Rett syndrome in the European Union, reversing an

U.S. stocks slightly up, Dow Jones gains 0.1%. Health care shares jump 2.8%, ON Semiconductor down 2

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m

-- European Commission decision expected in the coming months-- If approved, DAYBU® would become the

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

ACADIA Pharmaceuticals (NASDAQ:ACAD) affirms FY2026 sales outlook from $1.220 billion-$1.280 billion

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.02 per share which missed the

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original dat

-- DAYBUE STIX is a new powder formulation of trofinetide-- Recently published expert consensus reco

Top Wall Street analysts changed outlook on top names. See all rating changes, including upgrades, d

B of A Securities analyst Tazeen Ahmad upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight a